导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.79% | 1546/4773 |
| 近一周 | -1.31% | 2002/5465 |
| 近一月 | -3.30% | 2355/5421 |
| 近一季 | -5.14% | 1980/5231 |
| 近半年 | -0.17% | 1419/4920 |
| 近一年 | 5.82% | 1659/4394 |
| 近两年 | 68.95% | 1035/2954 |
| 近三年 | 39.78% | 769/2253 |
| 成立以来 | 33.02% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.98% 2595/4961 |
19.60% 1286/5312 |
- - |
- - |
| 2025 | 29.43% 1401/4813 |
0.89% 1742/3635 |
2.79% 1350/4076 |
28.11% 1283/4524 |
-2.58% 3171/4813 |
| 2024 | 12.17% 1264/3463 |
-1.22% 1198/2808 |
-3.21% 1321/3014 |
17.96% 1089/3129 |
-0.55% 1457/3463 |
| 2023 | -8.59% 1031/2656 |
7.98% 506/2280 |
-4.94% 1323/2385 |
-3.45% 933/2515 |
-7.77% 2204/2655 |
| 2022 | -24.92% 1272/2207 |
-16.71% 1150/1919 |
3.48% 1145/2016 |
-15.35% 1272/2113 |
2.90% 806/2208 |
| 2021 | 1.47% 672/1822 |
-3.09% 758/1255 |
10.04% 497/1330 |
-5.56% 825/1466 |
0.76% 1065/1822 |
| 2020 | 23.64% 647/1250 |
-10.46% 780/1028 |
15.46% 500/1067 |
8.10% 735/1164 |
10.64% 588/1184 |
| 2019 | - - |
- - |
- - |
- - |
7.22% 466/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 添富中证长三角ETF VS. 长安沪深300非周期A(740101) |